Anzahl der Publikationen: 5
Zeitschriftenartikel
Staehler, Michael; Panic, Andrej; Goebell, Peter J.; Merling, Marie; Potthoff, Karin; Herrmann, Edwin; de Geeter, Patrick; Vannier, Corinne; Hogrefe, Cathrin; Marschner, Norbert und Gruenwald, Viktor
(2020):
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of theFLIPPERtrial.
In: International Journal of Cancer, Bd. 148, Nr. 4: S. 950-960
[PDF, 823kB]
Staehler, Michael; Stöckle, Michael; Christoph, Daniel C.; Stenzl, Arnulf; Potthoff, Karin; Grimm, Marc-Oliver; Klein, Dunja; Harde, Johanna; Brüning, Fabian; Goebell, Peter J.; Augustin, Marinela; Roos, Frederik; Benz-Rüd, Iris; Marschner, Norbert und Grünwald, Viktor
(2020):
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
In: International Journal of Cancer, Bd. 148, Nr. 7: S. 1685-1694
Staehler, Michael; Goebell, Peter J.; Müller, Lothar; Emde, Till-Oliver; Wetzel, Natalie; Kruggel, Lisa; Jaenicke, Martina und Marschner, Norbert
(2019):
Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
In: International Journal of Cancer, Bd. 146, Nr. 5: S. 1307-1315
Bergmann, Lothar; Kube, Ulrich; Doehn, Christian; Steiner, Thomas; Goebell, Peter J.; Kindler, Manfred; Herrmann, Edwin; Janssen, Jan; Weikert, Steffen; Scheffler, Michael T.; Schmitz, Jörg; Albrecht, Michael und Staehler, Michael
(2015):
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.
In: BMC Cancer
15:303
[PDF, 1MB]
Bergmann, Lothar; Goebell, Peter J.; Kube, Ulrich; Kindler, Manfred; Herrmann, Edwin; Janssen, Jan; Schmitz, Joerg; Weikert, Steffen; Steiner, Gabriel; Jakob, Andreas; Staehler, Michael D.; Steiner, Thomas; Overkamp, Friedrich; Albrecht, Michael; Guderian, Gernot und Doehn, Christian
(2013):
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study.
In: Onkologie, Nr. 3: S. 95-100
[PDF, 441kB]
Diese Liste wurde am
Sat Aug 3 18:13:31 2024 CEST
erstellt.